8:00 am

Morning Coffee

8:50 am Chair’s Opening Remarks

Exploring the Challenges of Tumor Resistance

9:00 am Harnessing Disseminated PDX Models to Advance Drug Discovery for Hematologic Cancers


• Understanding how disease progresses in different tissues in disseminated models
• Recapitulating the bone marrow niche ex vivo to inform in vivo study design
• Employing PDX models to identify clinically actionable combinations

9:30 am Epigenetic Cell Reprograming to Reduce Target Resistance


• Identifying transcription factors which can inhibit reprograming to lessen tumor resistance
• Exploring potential drug combinations which can overcome resistance and prevent tumor growth simultaneously
• Discussing the possibilities of artificial transcription factors to epigenetically target gene expression

10:00 am Mastermind: Tissue Sample Heterogeneity – Utilizing Cell Lines to Ensure Minimal Tumor Variation & Promote Clinical Efficacy

  • Sarah Knutson Director of Preclinical Biology, Twenty Eight- Seven Therapeutics


• Explore how to harness cell lines to tackle the challenges surrounding cancer heterogeneity
• Produce a framework of how to overcome target resistance to produce an efficacious therapy

10:45 am

Morning Break

Deep Diving into the Next Generation of Preclinical Tumor Models

11:30 am Combination Approach: Using Chicken Egg In Vitro Cell Cultures for High-Value Identification of Oncology Candidates


• How to use INOVOTION’s technology to open new perspectives of in vivo screening in oncology and immuno-oncology
• Why does the chicken embryo model have several advantages for drug discovery of anti-cancer treatments over traditional in vivo models?
• The chicken embryo model fills the gap between in vitro studies and in vivo mouse models, but is it possible to predict mouse data from chicken embryo results?

12:00 pm Utilizing & Translating CAR-T Cell Therapy to Solid Tumors


• Discuss the challenges surrounding the clinical activity of CAR-T cell therapy in solid tumors
• Exploring the degree of model translatability between preclinical studies and human CAR-T cell trials
• Next-generation CART cell therapy approaches combining novel targets with endogenous immune modulation

12:30 pm

Panel Discussion: Women & Diversity in Preclinical Oncology


This panel discussion will address the salient issue of understand and promoting diversity within the preclinical oncology community. Together, we will discuss career opportunities across the field, how to get more people working within the preclinical oncology space and what can we do to enhance diversity and retention within the field

1:30 pm

Networking Lunch

Analyzing Preclinical Toxicity, Safety & Dose Translation

2:30 pm 3D Organoids & Humanized Mice Models for Safety Profiling, Reducing Timeline & Animal Usage


• Considering in vivo solutions for early safety profiling in order to advance therapeutic efficacy
• Exploring the challenge of obtaining false negatives with the usage of in vitro assays
• Using in vivo assays to understand safety profiles with checkpoint inhibitors and bispecific therapies

3:00 pm Brain Tumor Models as a Platform to Advance Functional Diagnostics & Clinical Trials

  • Keith Ligon Director - Center For Patient Derived Models, Principal Investigator, Neuropathologist & Pathologist, Dana-Farber Cancer Institute


• Models of primary and metastatic brain cancer are highly valuable tools for precision medicine and preclinical testing
• Large number of common and rare brain cancer models allow large scale drug screening
• Novel approaches and technologies emerging to test patient models to personalize medicine and trials

3:30 pm Harnessing Genome-scale In Vivo T-Cell CRISPR Screen to Identify Novel Immuno-Oncology Targets For the Treatment of Solid Tumors

  • Louise Cadzow Senior Director, Head of In Vivo Pharmacology, KSQ Therapeutics


• Developed a novel CRISPRomics® platform that enabled in vivo genome-wide CRISPR/Cas9 screens in primary T-cells
• Systematic identification and validation of targets that can significantly improve T-cell function in solid tumor setting
• Developed CRISPR2 technology that enables the identification of optimal T-cell target combinations that drive anti-tumor response

4:00 pm Chair’s Closing Remarks & End of Conference